Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis

Clinical Infectious Diseases

Volumn 52, Issue 7, 2011, Pages 953-956

  Prendergast, Andrew ^a   Walker, A Sarah ^a   Mulenga, Veronica ^b   Chintu, Chifumbe ^b   Gibb, Diana M ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b UNIVERSITY TEACHING HOSPITAL   (Zambia)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; PLACEBO;

ADOLESCENT; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CHILD; CHILD GROWTH; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEIGHT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALARIA; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WEIGHT; ZAMBIA;

ADOLESCENT; ANEMIA; ANTIMALARIALS; BODY HEIGHT; BODY WEIGHT; CHEMOPREVENTION; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALARIA; MALE; PLACEBOS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; ZAMBIA;

EID: 79953761256     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir029     Document Type: Article

References (13)

1. Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004; 364:1865-71. (Pubitemid 39536090)
2. Mulenga V, Ford D, Walker AS, et al. Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS 2007; 21:77-84. (Pubitemid 44912540)
3. Walker AS, Ford D, Gilks CF, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 2010; 375:1278-86.
4. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS 2008; 22:97-105.
5. Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA. Cross sectional stature and weight reference curves for the UK. Arch Dis Child 1990; 1995:17-24.
6. Pantazis N, Touloumi G. Analyzing longitudinal data in the presence of informative drop-out: the jmre1 command. TATA J 2010; 10:226-51.
7. Arpadi SM. Growth failure in children with HIV infection. J Acquir Immune Defic Syndr 2000; 25(Suppl 1):S37-42.
8. Garly ML, Bale C, Martins CL, et al. Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau. BMJ 2006; 333:1245.
9. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71. (Pubitemid 44924494)
10. Humphrey JH. Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet 2009; 374:1032-5.
11. Kreuzer KA, Rockstroh JK, Jelkmann W, Theisen A, Spengler U, Sauerbruch T. Inadequate erythropoietin response to anaemia in HIV patients: relationship to serum levels of tumour necrosis factor-alpha, interleukin-6 and their soluble receptors. Br J Haematol 1997; 96:235-9. (Pubitemid 27077352)
12. UNAIDS. Children and AIDS: a Stocktaking Report. UNAIDS. 2007. Available at: data.unaids.org/pub/report/2007/20060116-stocktaking- report.pdf. Accessed 15 October 2010.
13. Date AA, Vitoria M, Granich R, Banda M, Fox MY, Gilks C. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ 2010; 88:253-9.